Onset and rate of striatal atrophy in preclinical Huntington disease
暂无分享,去创建一个
J. Brandt | E. Aylward | C. Ross | A. Rosenblatt | R. Margolis | K. Field | L. Gourley | V. Yallapragada | B. Sparks | B. Shpritz | K. Liang | H. Zhou | K. Liang | Barnett Shpritz
[1] H. Herzog,et al. Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease , 1993, Journal of Neurology.
[2] Elena Cattaneo,et al. Loss of normal huntingtin function: new developments in Huntington's disease research , 2001, Trends in Neurosciences.
[3] R H Myers,et al. Quantitative neuropathological changes in presymptomatic Huntington's disease , 2001, Annals of neurology.
[4] G. Pearlson,et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.
[5] R N Gunn,et al. Huntington's disease progression. PET and clinical observations. , 1999, Brain : a journal of neurology.
[6] W. Leslie,et al. Clinical deficits in Huntington disease correlate with reduced striatal uptake on iodine-123 epidepride single-photon emission tomography , 1999, European Journal of Nuclear Medicine.
[7] J. D. de Yébenes,et al. Clinical correlation of striatal 1H MRS changes in Huntington’s disease , 1999, Neurology.
[8] J. Brandt,et al. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. , 1999, Brain : a journal of neurology.
[9] Faith M. Gunning-Dixon,et al. Differential aging of the human striatum: a prospective MR imaging study. , 1998, AJNR. American journal of neuroradiology.
[10] G. Pearlson,et al. Structural evaluation of the prefrontal cortex in schizophrenia. , 1998, The American journal of psychiatry.
[11] T. Robbins,et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. , 1998, Brain : a journal of neurology.
[12] B R Rosen,et al. 1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.
[13] M. MacDonald,et al. CAG repeat number governs the development rate of pathology in Huntington's disease , 1997, Annals of neurology.
[14] G. Pearlson,et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease , 1997, Neurology.
[15] G. Pearlson,et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. , 1996, Archives of neurology.
[16] P Boesiger,et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. , 1996, Brain : a journal of neurology.
[17] D. Brooks,et al. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease , 1996, Annals of neurology.
[18] Jane S. Paulsen,et al. Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.
[19] S. Folstein,et al. Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. , 1995, American journal of human genetics.
[20] P. Diggle. Analysis of Longitudinal Data , 1995 .
[21] J. Brandt,et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at‐risk persons , 1994, Neurology.
[22] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[23] J C Mazziotta,et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. , 1992, Archives of neurology.
[24] S. Zeger,et al. Longitudinal data analysis using generalized linear models , 1986 .
[25] R J Leigh,et al. The measurement of abnormal movement: methods developed for Huntington's disease. , 1983, Neurobehavioral toxicology and teratology.